Filing Details

Accession Number:
0001415889-24-023551
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-09-17 18:44:23
Reporting Period:
2024-09-14
Accepted Time:
2024-09-17 18:44:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1370053 Anaptysbio Inc ANAB () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1239648 J Eric Loumeau C/O Anaptysbio, Inc.
10770 Wateridge Circle, Suite 210
San Diego CA 92121
Chief Legal Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-09-14 6,000 $0.00 10,740 No 4 M Direct
Common Stock Disposition 2024-09-16 2,220 $38.93 8,520 No 4 S Direct
Common Stock Acquisiton 2024-09-16 5,000 $14.02 13,520 No 4 M Direct
Common Stock Disposition 2024-09-16 6,500 $40.13 7,020 No 4 S Direct
Common Stock Disposition 2024-09-17 3,780 $38.41 3,240 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit Disposition 2024-09-14 6,000 $0.00 6,000 $0.00
Common Stock Employee Stock Option (right to buy) Disposition 2024-09-16 5,000 $0.00 5,000 $14.02
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 M Direct
73,000 2029-12-05 No 4 M Direct
Footnotes
  1. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  2. Includes 1,500 shares acquired under the Employee Stock Purchase Plan as of May 15, 2024.
  3. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  4. The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated June 10, 2024.
  5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.05 to $38.98 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. 50% of the total restricted stock units vested on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  7. The stock option vested and is exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
  8. In addition to the remaining options to purchase 73,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 355,310 shares of common stock, which options vest according to their terms.